Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal

Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning

(2016) Vittorio Martinelli et al.   Multiple Sclerosis Journal

Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning

(2016) Vittorio Martinelli et al.   Multiple Sclerosis Journal

Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8+ T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome

(2015) Guillaume Martin-Blondel et al.   ACTA NEUROPATHOLOGICA

Melanoma cell adhesion molecule-positive CD8 T lymphocytes mediate central nervous system inflammation

(2015) Catherine Larochelle et al.   ANNALS OF NEUROLOGY

Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report

(2015) Francesco Patti et al.   BMC Neurology

Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with natalizumab

(2015) Lena-Alexandra Beume et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Switching from natalizumab to fingolimod

(2015) Ludwig Kappos et al.   NEUROLOGY

Update on treatments in multiple sclerosis

(2015) Laure Michel et al.   PRESSE MEDICALE

Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis

(2014) R. Ratzer et al.   JOURNAL OF NEUROIMMUNOLOGY

Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients

(2014) Per Soelberg Sorensen et al.   JOURNAL OF NEUROLOGY

Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report

(2014) Maria Sepúlveda et al.   JOURNAL OF NEUROLOGY

Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis

(2014) A. Gueguen et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Significant clinical worsening after natalizumab withdrawal: Predictive factors

(2014) A Vidal-Jordana et al.   Multiple Sclerosis Journal

Fingolimod after natalizumab and the risk of short-term relapse

(2014) V. G. Jokubaitis et al.   NEUROLOGY

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

(2014) R. J. Fox et al.   NEUROLOGY

Maraviroc and JC Virus–Associated Immune Reconstitution Inflammatory Syndrome

(2014) Paul S. Giacomini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Switching From Natalizumab to Fingolimod in Multiple Sclerosis

(2014) Mikael Cohen et al.   JAMA Neurology

Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system

(2012) Catherine Larochelle et al.   BRAIN

Expression of CCR7 and CD45RA in CD4+ and CD8+ subsets in cerebrospinal fluid of 134 patients with inflammatory and non-inflammatory neurological diseases

(2012) Katherine M. Mullen et al.   JOURNAL OF NEUROIMMUNOLOGY

Lethal multiple sclerosis relapse after natalizumab withdrawal

(2012) V. Rigau et al.   NEUROLOGY

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy

(2011) Imke Metz et al.   ACTA NEUROPATHOLOGICA

CD161highCD8+T cells bear pathogenetic potential in multiple sclerosis

(2011) Viviana Annibali et al.   BRAIN

How do immune cells overcome the blood-brain barrier in multiple sclerosis?

(2011) Catherine Larochelle et al.   FEBS LETTERS

IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AFTER WITHDRAWAL OF NATALIZUMAB?

(2010) T. Lenhard et al.   NEUROLOGY

Preferential recruitment of interferon-γ-expressing TH17 cells in multiple sclerosis

(2009) Hania Kebir et al.   ANNALS OF NEUROLOGY

C-C chemokine receptor 6–regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE

(2009) Andrea Reboldi et al.   NATURE IMMUNOLOGY

Interleukin-17 Production in Central Nervous System-Infiltrating T Cells and Glial Cells Is Associated with Active Disease in Multiple Sclerosis

(2007) John S. Tzartos et al.   AMERICAN JOURNAL OF PATHOLOGY